Frequency Therapeutics Presented Data at the International Society for Stem Cell Research Supporting Progenitor Cell Activation to Restore Healthy Function in Multiple Tissue Types

, a company spearheading the movement to restore hearing
by harnessing the regenerative potential of progenitor cells in the
body, today announced a presentation delineating the company’s
proprietary platform, Progenitor Cell Activation (PCA™), was presented
at the International Society for Stem Cell Research (ISSCR) 2017 Annual
Meeting which took place in Boston, Massachusetts, on June 14-17. The
presentation, “Small molecule activation of progenitor cells as a means
of in situ tissue regeneration,” described a process that may provide a
novel means of addressing cellular deficiencies or malfunctions in many
diseases including hearing loss, dermatology, muscle and
gastrointestinal (GI) diseases. The presentation was conducted on
Friday, June 16 at 7:00pm ET by Chris Loose, Ph.D., Co-founder and CSO
of Frequency Therapeutics.

Scientists have worked for decades pushing targeted cells to regenerate.
The applicability of tissue regeneration is limited by the complexities
of cell therapy, including cell delivery, gene expression and
functionality. Unlike previous approaches which resulted in forced
conversion of Lgr5+ cells into the desired cell type, Frequency’s PCA
technology uses a precise and controlled application of small molecules
to activate dormant progenitor cells within the body, causing them to
divide and differentiate into their designated target cells. Frequency’s
presentation highlighted the Company’s PCA Platform, initially targeting
cochlear hair cell regeneration for noise-induced hearing loss, as a
viable approach to develop a whole new category of disease-modifying
therapeutics for a wide range of degenerative conditions.

“Progenitor Cell Activation is a system where the local delivery of
small molecules to dormant Lgr5 progenitor cells could produce profound
therapeutic opportunities across a vast number of disease areas that
exhibit high, unmet medical needs,” said Dr. Loose. “We believe PCA
technology could be used to modulate cells in situ to address a number
of diseases with minimal safety risk. Our first indication in hearing
loss has produced positive results in preclinical studies, and we look
forward to presenting further information as we move our lead program

“Our PCA platform presents a robust opportunity to address many
debilitating issues, and expand to therapeutic areas where there are few
or no options currently available,” added David Lucchino, President,
Co-Founder and CEO of Frequency. “The body has an innate, but sometimes
dormant ability to heal itself. Activating the body’s own resources
could overcome biological barriers that still exist within the overall
drug development space to address medical needs like hearing impairment,
skin disorders, gastrointestinal diseases and muscle regeneration.”

A team led by Frequency’s scientific co-founders published research
highlighting the PCA approach to regenerate inner ear sensory hair cells
in early 2017. The paper titled, “Clonal
Expansion of Lgr5-Positive Cells from Mammalian Cochlea and High-Purity
Generation of Sensory Hair Cells
,” was a February cover feature in
the journal Cell Reports, and can be accessed in the current online


Frequency’s precise and controlled approach transiently causes Lgr5+
progenitor cells to divide and differentiate, much like what is seen in
naturally regenerating tissues such as the skin and intestine. Frequency
activates ‘stemness’ through mimicking signals provided by neighboring
cells (the stem cell niche) with small molecules, and this proprietary
approach is known as the Progenitor Cell Activation (PCA™) platform.
Frequency believes that PCA has the potential to yield a whole new
category of disease-modifying therapeutics for a wide range of
degenerative conditions. To fuel its drug discovery programs, Frequency
is leveraging a PCA screening platform using primary human cells.
Frequency’s initial focus is on chronic noise induced hearing loss.
Other potential applications include skin disorders, gastrointestinal
diseases, and diabetes.


Frequency Therapeutics develops small molecule drugs that activate
progenitor cells within the body to restore healthy tissue. Through the
transitory activation of these progenitor cells, Frequency enables
disease modification without the complexity of genetic engineering. Our
lead program re-creates sensory cells in the inner ear to treat chronic
noise induced hearing loss, which affects over 30 million people in the
U.S. alone.


Media Inquiries:
MacDougall Biomedical Communications
Tuck or Kari Watson
+1 781-235-3060